Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

54.83 +1.31 (+2.45%)
Official Closing Price Updated: 7:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 8% in the afternoon session after the U.S. Food and Drug Administration raised concerns about unapproved GLP-1 drugs used for weight... 
Via StockStory
Topics Supply Chain
Exposures Product Safety Supply Chain
Why Hims & Hers Stock Tumbled on Tuesday
Bank of America just delivered an incredibly back-handed compliment to Hims & Hers stock. 
Via The Motley Fool
2 Healthcare Stocks with Solid Fundamentals and 1 to Brush Off
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Check Out What Whales Are Doing With HIMS
Via Benzinga
Should You Buy Hims & Hers Stock on the Dip?
Via The Motley Fool
Forecasting The Future: 15 Analyst Projections For Hims & Hers Health
Via Benzinga
Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?
Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug. 
Via MarketBeat
Why Hims & Hers Stock Popped on Monday
Morgan Stanley had great news for Hims & Hers stock today, so why didn't it upgrade the stock? 
Via The Motley Fool
2 High-Flying Stocks with Exciting Potential and 1 to Turn Down
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated... 
Via StockStory
Defiance Launches RKLX and HIMZ: 2X Leveraged ETFs for Rocket Lab and Hims & Hers
From Defiance ETFs
Via GlobeNewswire
Why Hims & Hers Stock Just Collapsed
Via The Motley Fool
Market Whales and Their Recent Bets on HIMS Options
Via Benzinga
Why Hims & Hers Health Stock Just Popped
Via The Motley Fool
4 Top Stocks to Buy Under $100
Here are four stocks to buy now that could offer investors upside in the short and long terms. 
Via The Motley Fool
Hims & Hers Stock Is Down 50% From Its High, but Is This a Buying Opportunity?
Shutting down an acquisition caught investor attention, but there's more to the story. 
Via The Motley Fool
The State of Weight Loss Drugs
Via The Motley Fool
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease. 
Via MarketBeat
Exposures Product Safety
Why Hims & Hers Health Stock Sank This Week
Via The Motley Fool
3 Cold Stocks That Can Bounce Back This Week
These three stocks tumbled by at least 20% last week, but they may not be down for long. 
Via The Motley Fool
MarketBeat Week in Review – 03/03 - 03/07
Stocks had another down week despite a mostly benign jobs report; and with the latest reads on inflation coming next week the uncertainty may continue 
Via MarketBeat
Topics Economy
Exposures Interest Rates
This Could Be a Huge Blow to Hims & Hers Health Stock
Via The Motley Fool
Why Novo Nordisk Stock Outpaced the Market Today and Hims & Hers Lagged It
Via The Motley Fool
Why Is Hims & Hers Health Stock Trading Lower On Wednesday?
Hims & Hers Health stock drops over 20% after the FDA removes semaglutide from the shortage list. Novo Nordisk launches a direct delivery service for Wegovy. 
Via Benzinga
Exposures Product Safety
Novo Nordisk Slashes Wegovy Price, Undercutting Hims & Hers Health
The news slammed Hims stock. Hims & Hers sells knockoff versions of semaglutide, the chemical backbone behind Wegovy. 
Via Investor's Business Daily
Missed the Hims & Hers Rally? Clover Health Could Be Next
After a steep decline from its all-time high prices, shares of Hims & Hers are now recovering to show investor interest in the space. 
Via MarketBeat
EXCLUSIVE: February's 20 Most-Searched Tickers On Benzinga Pro – Where Do Tesla, Palantir, Alibaba, Nvidia Rank?
These were the 20 tickers that Benzinga readers searched for the most during the month of February. 
Via Benzinga
Tech Sector Hammered As Trump's Tariff Plans Spark Market Selloff: Nvidia, ARM, Super Micro Lead Tech Bloodbath
U.S. markets suffered a steep selloff Monday as President Donald Trump announced sweeping new tariffs, extending last week's losses and driving declines across all major sectors. 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Short Term Relief Likely
Post earnings has seen little bullish follow-through, and this typically means the broad market won’t have much to shout about over the coming weeks. 
Via Talk Markets
Topics ETFs Stocks / Equities
Hims & Hers Stocks Sinks Despite Huge Revenue Growth. Is This a Buying Opportunity in the Stock?
Via The Motley Fool
Sixty Percent Of The Time, It Works Every Time
​​​​​​​The past few weeks have brought a dramatic change in investor sentiment. 
Via Talk Markets
Topics Stocks / Equities
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.